Paediatric pulmonary hypertension and sildenafil: current practice and controversies

A. J. Wardle, R. M. Tulloh*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

25 Citations (Scopus)


In recent times, paediatric pulmonary arterial hypertension management has been transformed to focus on disease modifying strategies that improve both quality of life and survival, rather than just symptom palliation. Sildenafil, a phosphodiesterase-V inhibitor, has been at the centre of this. Despite controversial beginnings, its success in treating pulmonary arterial hypertension has led to its consideration for related pathologies such as persistent pulmonary hypertension of the newborn and bronchopulmonary dysplasia, as well as the development of a range of alternative formulations. However, this has caused its own controversy and confusion regarding the use of sildenafil in younger patients. In addition, recent data regarding long-term mortality and the repeal of US drugs approval have complicated the issue. Despite such setbacks, sildenafil continues to be a major component of the contemporary care of paediatric pulmonary hypertension in a variety of contexts, and this does not seem likely to change in the foreseeable future.

Original languageEnglish
Pages (from-to)141-147
Number of pages7
JournalArchives of Disease in Childhood: Education and Practice Edition
Issue number4
Early online date15 Jun 2013
Publication statusPublished - Aug 2013


Dive into the research topics of 'Paediatric pulmonary hypertension and sildenafil: current practice and controversies'. Together they form a unique fingerprint.

Cite this